|Tested species reactivity||Human, Non-human primate|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant <i>Vaccinia</i> virus encoding CD222.|
|Storage buffer||PBS with 0.2% BSA|
|Contains||15mM sodium azide|
|Storage Conditions||4° C, store in dark, DO NOT FREEZE!|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||20 ul/10^6 cells|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Miscellaneous PubMed (MISC)||See 1 publications below|
This antibody recognizes an epitope between domains 2 and 5 of CD222 (IGF2 receptor), a ubiquitously expressed 250 kDa multifunctional type I transmembrane protein. The majority of CD222 is found in the late endosomal/prelysosomal compartment, 5-10% in the plasma membrane and the truncated (220 kDa) form of CD222 is present in human and bovine serum.
CD222 (CIMPR, cation-independent mannose 6-phosphate receptor; IGF2 receptor) is a ubiquitously expressed 250 kDa transmembrane protein. No more than 10% of CD222 is present on the cell surface where it serves as a multifunctional receptor. Intracellular (major) fraction of CD222 is involved in transport of newly synthesized lysosomal enzymes modified by mannose 6-phosphate from Golgi apparatus to lysosomes. The cell surface CD222 binds and internalizes exogeneous mannose 6-phosphate-containing ligands. Importantly, CD222 is crutial for internalization and degradation of insulin-like growth factor 2, thus controling cell growth. CD222 also complexes CD87 (urokinase-type plasminogen-activator receptor), plasminogen and latent TGF-beta, last but not least CD222 serves as a receptor for heparanase and even for Listeria.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death.
MA1-10148 was used in immunocytochemistry to study the relationship between the P2X7 receptor and ATP release after ivermectin treatment
|Draganov D,Gopalakrishna-Pillai S,Chen YR,Zuckerman N,Moeller S,Wang C,Ann D,Lee PP||Scientific reports (5:null)||2015|